Heart transplantation has become a valuable and well-accepted treatment option for end-stage heart failure. Rejection of the transplanted heart by the recipient's body is a risk to the success of the procedure, and life-long immunosuppression is necessary to avoid this. Clear evidence is required to identify the best, safest and most effective immunosuppressive treatment strategy for heart transplant recipients. To date, there is no consensus on the use of immunosuppressive antibodies against T-cells for induction after heart transplantation.
Cochrane Database of Systematic Reviews, 2013, Vol 12, Issue 12, p. 1-158
Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Review